Hypermutation In Pancreatic Cancer

Jeremy L. Humphris; Ann-Marie Patch; Katia Nones; Peter J. Bailey; Amber L. Johns; Skye Mckay; David K. Chang; David K. Miller; Marina Pajic; Karin S. Kassahn; Michael C.J. Quinn; Timothy J.C. Bruxner; Angelika N. Christ; Ivon Harliwong; Senel Idrisoglu; Suzanne Manning; Craig Nourse; Ehsan Nourbakhsh; Andrew Stone; Peter J. Wilson; Matthew Anderson; J. Lynn Fink; Oliver Holmes; Stephen Kazakoff; Conrad Leonard; Felicity Newell; Nick Waddell; Scott Wood; Ronald S. Mead; Qinying Xu; Jianmin Wu; Mark Pinese; Mark J. Cowley; Marc D. Jones; Adnan M. Nagrial; Venessa T. Chin; Lorraine A. Chantrill; Amanda Mawson; Angela Chou; Christopher J. Scarlett; Andreia V. Pinho; Ilse Rooman; Marc Giry-Laterriere; Jaswinder S. Samra; James G. Kench; Neil D. Merrett; Christopher W. Toon; Krishna Epari; Nam Q. Nguyen; Andrew Barbour; Nikolajs Zeps; Nigel B. Jamieson; Colin J. Mckay; C. Ross Carter; Euan J. Dickson; Janet S. Graham; Fraser Duthie; Karin Oien; Jane Hair; Jennifer P. Morton; Owen J. Sansom; Robert Grützmann; Ralph H. Hruban; Anirban Maitra; Christine A. Iacobuzio-Donahue; Richard D. Schulick; Christopher L. Wolfgang; Richard A. Morgan; Rita T. Lawlor; Borislav Rusev; Vincenzo Corbo; Roberto Salvia; Ivana Cataldo; Giampaolo Tortora; Margaret A. Tempero; Oliver Hofmann; James R. Eshleman; Christian Pilarsky; Aldo Scarpa; Elizabeth A. Musgrove; Anthony J. Gill; John V. Pearson; Sean M. Grimmond; Nicola Waddell; Andrew V. Biankin

doi:10.1053/j.gastro.2016.09.060

Hypermutation In Pancreatic Cancer

Jeremy L. Humphris
, Ann-Marie Patch
, Katia Nones
, Peter J. Bailey
, Amber L. Johns
, Skye Mckay
, David K. Chang
, David K. Miller
, Marina Pajic
, Karin S. Kassahn
, Michael C.J. Quinn
, Timothy J.C. Bruxner
, Angelika N. Christ
, Ivon Harliwong
, Senel Idrisoglu
, Suzanne Manning
, Craig Nourse
, Ehsan Nourbakhsh
, Andrew Stone
, Peter J. Wilson

Matthew Anderson, J. Lynn Fink, Oliver Holmes, Stephen Kazakoff, Conrad Leonard, Felicity Newell, Nick Waddell, Scott Wood, Ronald S. Mead, Qinying Xu, Jianmin Wu, Mark Pinese, Mark J. Cowley, Marc D. Jones, Adnan M. Nagrial, Venessa T. Chin, Lorraine A. Chantrill, Amanda Mawson, Angela Chou, Christopher J. Scarlett, Andreia V. Pinho, Ilse Rooman, Marc Giry-Laterriere, Jaswinder S. Samra, James G. Kench, Neil D. Merrett, Christopher W. Toon, Krishna Epari, Nam Q. Nguyen, Andrew Barbour, Nikolajs Zeps, Nigel B. Jamieson, Colin J. Mckay, C. Ross Carter, Euan J. Dickson, Janet S. Graham, Fraser Duthie, Karin Oien, Jane Hair, Jennifer P. Morton, Owen J. Sansom, Robert Grützmann, Ralph H. Hruban, Anirban Maitra, Christine A. Iacobuzio-Donahue, Richard D. Schulick, Christopher L. Wolfgang, Richard A. Morgan, Rita T. Lawlor, Borislav Rusev, Vincenzo Corbo, Roberto Salvia, Ivana Cataldo, Giampaolo Tortora, Margaret A. Tempero, Oliver Hofmann, James R. Eshleman, Christian Pilarsky, Aldo Scarpa, Elizabeth A. Musgrove, Anthony J. Gill, John V. Pearson, Sean M. Grimmond, Nicola Waddell, Andrew V. Biankin

Garvan Institute of Medical Research
Queensland Institute of Medical Research
University of Queensland
University of Glasgow
Royal North Shore Hospital
Bankstown-Lidcombe Hospital
Fiona Stanley Hospital
Royal Adelaide Hospital
Department of Surgery, Princess Alexandra Hospital
University of Western Australia
Glasgow Royal Infirmary
Southern General Hospital Glasgow
Queen Elizabeth University Hospital
The Beatson Institute for Cancer Research
Friedrich-Alexander University Erlangen-Nürnberg
Johns Hopkins University
Hospital Verona
University of California at San Francisco
Australian Pancreatic Cancer Genome Initiative

Risultato della ricerca: Contributo in rivista › Articolo

107 Citazioni (Scopus)

Abstract

Pancreatic cancer is molecularly diverse, with few effective therapies. Increased mutation burden and defective DNA repair are associated with response to immune checkpoint inhibitors in several other cancer types. We interrogated 385 pancreatic cancer genomes to define hypermutation and its causes. Mutational signatures inferring defects in DNA repair were enriched in those with the highest mutation burdens. Mismatch repair deficiency was identified in 1% of tumors harboring different mechanisms of somatic inactivation of MLH1 and MSH2. Defining mutation load in individual pancreatic cancers and the optimal assay for patient selection may inform clinical trial design for immunotherapy in pancreatic cancer.

Lingua originale	Inglese
pagine (da-a)	68-74
Numero di pagine	7
Rivista	Gastroenterology
Volume	152
DOI	https://doi.org/10.1053/j.gastro.2016.09.060
Stato di pubblicazione	Pubblicato - 2017

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Keywords

Cancer Genetics
Pancreatic Adenocarcinoma
Sequencing
Somatic Rearrangement

Accesso al documento

10.1053/j.gastro.2016.09.060

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Humphris, J. L., Patch, A.-M., Nones, K., Bailey, P. J., Johns, A. L., Mckay, S., Chang, D. K., Miller, D. K., Pajic, M., Kassahn, K. S., Quinn, M. C. J., Bruxner, T. J. C., Christ, A. N., Harliwong, I., Idrisoglu, S., Manning, S., Nourse, C., Nourbakhsh, E., Stone, A., ... Biankin, A. V. (2017). Hypermutation In Pancreatic Cancer. Gastroenterology, 152, 68-74. https://doi.org/10.1053/j.gastro.2016.09.060

@article{11d01646fe084ff0bc0aea4812eed986,

title = "Hypermutation In Pancreatic Cancer",

abstract = "Pancreatic cancer is molecularly diverse, with few effective therapies. Increased mutation burden and defective DNA repair are associated with response to immune checkpoint inhibitors in several other cancer types. We interrogated 385 pancreatic cancer genomes to define hypermutation and its causes. Mutational signatures inferring defects in DNA repair were enriched in those with the highest mutation burdens. Mismatch repair deficiency was identified in 1\% of tumors harboring different mechanisms of somatic inactivation of MLH1 and MSH2. Defining mutation load in individual pancreatic cancers and the optimal assay for patient selection may inform clinical trial design for immunotherapy in pancreatic cancer.",

keywords = "Cancer Genetics, Pancreatic Adenocarcinoma, Sequencing, Somatic Rearrangement, Cancer Genetics, Pancreatic Adenocarcinoma, Sequencing, Somatic Rearrangement",

author = "Humphris, \{Jeremy L.\} and Ann-Marie Patch and Katia Nones and Bailey, \{Peter J.\} and Johns, \{Amber L.\} and Skye Mckay and Chang, \{David K.\} and Miller, \{David K.\} and Marina Pajic and Kassahn, \{Karin S.\} and Quinn, \{Michael C.J.\} and Bruxner, \{Timothy J.C.\} and Christ, \{Angelika N.\} and Ivon Harliwong and Senel Idrisoglu and Suzanne Manning and Craig Nourse and Ehsan Nourbakhsh and Andrew Stone and Wilson, \{Peter J.\} and Matthew Anderson and Fink, \{J. Lynn\} and Oliver Holmes and Stephen Kazakoff and Conrad Leonard and Felicity Newell and Nick Waddell and Scott Wood and Mead, \{Ronald S.\} and Qinying Xu and Jianmin Wu and Mark Pinese and Cowley, \{Mark J.\} and Jones, \{Marc D.\} and Nagrial, \{Adnan M.\} and Chin, \{Venessa T.\} and Chantrill, \{Lorraine A.\} and Amanda Mawson and Angela Chou and Scarlett, \{Christopher J.\} and Pinho, \{Andreia V.\} and Ilse Rooman and Marc Giry-Laterriere and Samra, \{Jaswinder S.\} and Kench, \{James G.\} and Merrett, \{Neil D.\} and Toon, \{Christopher W.\} and Krishna Epari and Nguyen, \{Nam Q.\} and Andrew Barbour and Nikolajs Zeps and Jamieson, \{Nigel B.\} and Mckay, \{Colin J.\} and Carter, \{C. Ross\} and Dickson, \{Euan J.\} and Graham, \{Janet S.\} and Fraser Duthie and Karin Oien and Jane Hair and Morton, \{Jennifer P.\} and Sansom, \{Owen J.\} and Robert Gr{\"u}tzmann and Hruban, \{Ralph H.\} and Anirban Maitra and Iacobuzio-Donahue, \{Christine A.\} and Schulick, \{Richard D.\} and Wolfgang, \{Christopher L.\} and Morgan, \{Richard A.\} and Lawlor, \{Rita T.\} and Borislav Rusev and Vincenzo Corbo and Roberto Salvia and Ivana Cataldo and Giampaolo Tortora and Tempero, \{Margaret A.\} and Oliver Hofmann and Eshleman, \{James R.\} and Christian Pilarsky and Aldo Scarpa and Musgrove, \{Elizabeth A.\} and Gill, \{Anthony J.\} and Pearson, \{John V.\} and Grimmond, \{Sean M.\} and Nicola Waddell and Biankin, \{Andrew V.\}",

year = "2017",

doi = "10.1053/j.gastro.2016.09.060",

language = "English",

volume = "152",

pages = "68--74",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders",

}

Humphris, JL, Patch, A-M, Nones, K, Bailey, PJ, Johns, AL, Mckay, S, Chang, DK, Miller, DK, Pajic, M, Kassahn, KS, Quinn, MCJ, Bruxner, TJC, Christ, AN, Harliwong, I, Idrisoglu, S, Manning, S, Nourse, C, Nourbakhsh, E, Stone, A, Wilson, PJ, Anderson, M, Fink, JL, Holmes, O, Kazakoff, S, Leonard, C, Newell, F, Waddell, N, Wood, S, Mead, RS, Xu, Q, Wu, J, Pinese, M, Cowley, MJ, Jones, MD, Nagrial, AM, Chin, VT, Chantrill, LA, Mawson, A, Chou, A, Scarlett, CJ, Pinho, AV, Rooman, I, Giry-Laterriere, M, Samra, JS, Kench, JG, Merrett, ND, Toon, CW, Epari, K, Nguyen, NQ, Barbour, A, Zeps, N, Jamieson, NB, Mckay, CJ, Carter, CR, Dickson, EJ, Graham, JS, Duthie, F, Oien, K, Hair, J, Morton, JP, Sansom, OJ, Grützmann, R, Hruban, RH, Maitra, A, Iacobuzio-Donahue, CA, Schulick, RD, Wolfgang, CL, Morgan, RA, Lawlor, RT, Rusev, B, Corbo, V, Salvia, R, Cataldo, I, Tortora, G, Tempero, MA, Hofmann, O, Eshleman, JR, Pilarsky, C, Scarpa, A, Musgrove, EA, Gill, AJ, Pearson, JV, Grimmond, SM, Waddell, N & Biankin, AV 2017, 'Hypermutation In Pancreatic Cancer', Gastroenterology, vol. 152, pagg. 68-74. https://doi.org/10.1053/j.gastro.2016.09.060

TY - JOUR

T1 - Hypermutation In Pancreatic Cancer

AU - Humphris, Jeremy L.

AU - Patch, Ann-Marie

AU - Nones, Katia

AU - Bailey, Peter J.

AU - Johns, Amber L.

AU - Mckay, Skye

AU - Chang, David K.

AU - Miller, David K.

AU - Pajic, Marina

AU - Kassahn, Karin S.

AU - Quinn, Michael C.J.

AU - Bruxner, Timothy J.C.

AU - Christ, Angelika N.

AU - Harliwong, Ivon

AU - Idrisoglu, Senel

AU - Manning, Suzanne

AU - Nourse, Craig

AU - Nourbakhsh, Ehsan

AU - Stone, Andrew

AU - Wilson, Peter J.

AU - Anderson, Matthew

AU - Fink, J. Lynn

AU - Holmes, Oliver

AU - Kazakoff, Stephen

AU - Leonard, Conrad

AU - Newell, Felicity

AU - Waddell, Nick

AU - Wood, Scott

AU - Mead, Ronald S.

AU - Xu, Qinying

AU - Wu, Jianmin

AU - Pinese, Mark

AU - Cowley, Mark J.

AU - Jones, Marc D.

AU - Nagrial, Adnan M.

AU - Chin, Venessa T.

AU - Chantrill, Lorraine A.

AU - Mawson, Amanda

AU - Chou, Angela

AU - Scarlett, Christopher J.

AU - Pinho, Andreia V.

AU - Rooman, Ilse

AU - Giry-Laterriere, Marc

AU - Samra, Jaswinder S.

AU - Kench, James G.

AU - Merrett, Neil D.

AU - Toon, Christopher W.

AU - Epari, Krishna

AU - Nguyen, Nam Q.

AU - Barbour, Andrew

AU - Zeps, Nikolajs

AU - Jamieson, Nigel B.

AU - Mckay, Colin J.

AU - Carter, C. Ross

AU - Dickson, Euan J.

AU - Graham, Janet S.

AU - Duthie, Fraser

AU - Oien, Karin

AU - Hair, Jane

AU - Morton, Jennifer P.

AU - Sansom, Owen J.

AU - Grützmann, Robert

AU - Hruban, Ralph H.

AU - Maitra, Anirban

AU - Iacobuzio-Donahue, Christine A.

AU - Schulick, Richard D.

AU - Wolfgang, Christopher L.

AU - Morgan, Richard A.

AU - Lawlor, Rita T.

AU - Rusev, Borislav

AU - Corbo, Vincenzo

AU - Salvia, Roberto

AU - Cataldo, Ivana

AU - Tortora, Giampaolo

AU - Tempero, Margaret A.

AU - Hofmann, Oliver

AU - Eshleman, James R.

AU - Pilarsky, Christian

AU - Scarpa, Aldo

AU - Musgrove, Elizabeth A.

AU - Gill, Anthony J.

AU - Pearson, John V.

AU - Grimmond, Sean M.

AU - Waddell, Nicola

AU - Biankin, Andrew V.

PY - 2017

Y1 - 2017

N2 - Pancreatic cancer is molecularly diverse, with few effective therapies. Increased mutation burden and defective DNA repair are associated with response to immune checkpoint inhibitors in several other cancer types. We interrogated 385 pancreatic cancer genomes to define hypermutation and its causes. Mutational signatures inferring defects in DNA repair were enriched in those with the highest mutation burdens. Mismatch repair deficiency was identified in 1% of tumors harboring different mechanisms of somatic inactivation of MLH1 and MSH2. Defining mutation load in individual pancreatic cancers and the optimal assay for patient selection may inform clinical trial design for immunotherapy in pancreatic cancer.

AB - Pancreatic cancer is molecularly diverse, with few effective therapies. Increased mutation burden and defective DNA repair are associated with response to immune checkpoint inhibitors in several other cancer types. We interrogated 385 pancreatic cancer genomes to define hypermutation and its causes. Mutational signatures inferring defects in DNA repair were enriched in those with the highest mutation burdens. Mismatch repair deficiency was identified in 1% of tumors harboring different mechanisms of somatic inactivation of MLH1 and MSH2. Defining mutation load in individual pancreatic cancers and the optimal assay for patient selection may inform clinical trial design for immunotherapy in pancreatic cancer.

KW - Cancer Genetics

KW - Pancreatic Adenocarcinoma

KW - Sequencing

KW - Somatic Rearrangement

KW - Cancer Genetics

KW - Pancreatic Adenocarcinoma

KW - Sequencing

KW - Somatic Rearrangement

UR - http://hdl.handle.net/10807/171762

U2 - 10.1053/j.gastro.2016.09.060

DO - 10.1053/j.gastro.2016.09.060

M3 - Article

SN - 0016-5085

VL - 152

SP - 68

EP - 74

JO - Gastroenterology

JF - Gastroenterology

ER -

Hypermutation In Pancreatic Cancer

Abstract

OSS delle Nazioni Unite

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo